An Open-label Study to Evaluate the Efficacy and Safety of ABT-450/r/ABT-267 Co-administered With Ribavirin for 12 or 16 Weeks in Treatment-Naive and Treatment-Experienced Japanese Adults With Genotype 2 Chronic HCV Infection With and Without Compensated Cirrhosis (GIFT-II)
Phase 3
- Conditions
- Hepatitis C Virus
- Registration Number
- JPRN-jRCT2080222382
- Lead Sponsor
- AbbVie GK
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Chronic HCV-infection prior to study enrollment
-Screening laboratory result indicating HCV genotype 2 infection
-Subject has plasma HCV RNA level greater than 10,000 IU/mL at Screening
-Voluntarily sign an informed consent
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method